Insight Biotechnology Limited 03093313 false 2024-01-01 2024-12-31 2024-12-31 The principal activity of the company is that of distributors of research reagents Digita Accounts Production Advanced 6.30.9574.0 true false true 03093313 2024-01-01 2024-12-31 03093313 2024-12-31 03093313 bus:OrdinaryShareClass1 2024-12-31 03093313 core:CurrentFinancialInstruments 2024-12-31 03093313 core:CurrentFinancialInstruments core:WithinOneYear 2024-12-31 03093313 core:FurnitureFittingsToolsEquipment 2024-12-31 03093313 core:MotorVehicles 2024-12-31 03093313 core:OtherPropertyPlantEquipment 2024-12-31 03093313 core:OtherRelatedParties 2024-12-31 03093313 bus:SmallEntities 2024-01-01 2024-12-31 03093313 bus:AuditExemptWithAccountantsReport 2024-01-01 2024-12-31 03093313 bus:FilletedAccounts 2024-01-01 2024-12-31 03093313 bus:SmallCompaniesRegimeForAccounts 2024-01-01 2024-12-31 03093313 bus:RegisteredOffice 2024-01-01 2024-12-31 03093313 bus:Director1 2024-01-01 2024-12-31 03093313 bus:Director2 2024-01-01 2024-12-31 03093313 bus:Director3 2024-01-01 2024-12-31 03093313 bus:OrdinaryShareClass1 2024-01-01 2024-12-31 03093313 bus:PrivateLimitedCompanyLtd 2024-01-01 2024-12-31 03093313 bus:Agent1 2024-01-01 2024-12-31 03093313 core:FurnitureFittingsToolsEquipment 2024-01-01 2024-12-31 03093313 core:MotorVehicles 2024-01-01 2024-12-31 03093313 core:OfficeEquipment 2024-01-01 2024-12-31 03093313 core:OtherPropertyPlantEquipment 2024-01-01 2024-12-31 03093313 core:PlantMachinery 2024-01-01 2024-12-31 03093313 core:OtherRelatedParties 2024-01-01 2024-12-31 03093313 core:OtherRelatedParties core:RenderingOrReceivingServices 2024-01-01 2024-12-31 03093313 core:Subsidiary1 2024-01-01 2024-12-31 03093313 core:Subsidiary1 1 2024-01-01 2024-12-31 03093313 core:Subsidiary1 countries:England 2024-01-01 2024-12-31 03093313 countries:EnglandWales 2024-01-01 2024-12-31 03093313 2023-12-31 03093313 core:CostValuation 2023-12-31 03093313 core:ProvisionsForImpairmentInvestments 2023-12-31 03093313 core:FurnitureFittingsToolsEquipment 2023-12-31 03093313 core:MotorVehicles 2023-12-31 03093313 core:OtherPropertyPlantEquipment 2023-12-31 03093313 core:OtherRelatedParties 2023-12-31 03093313 2023-01-01 2023-12-31 03093313 2023-12-31 03093313 bus:OrdinaryShareClass1 2023-12-31 03093313 core:CurrentFinancialInstruments 2023-12-31 03093313 core:CurrentFinancialInstruments core:WithinOneYear 2023-12-31 03093313 core:FurnitureFittingsToolsEquipment 2023-12-31 03093313 core:MotorVehicles 2023-12-31 03093313 core:OtherPropertyPlantEquipment 2023-12-31 03093313 core:OtherRelatedParties 2023-12-31 03093313 core:OtherRelatedParties 2023-01-01 2023-12-31 03093313 core:OtherRelatedParties core:RenderingOrReceivingServices 2023-01-01 2023-12-31 03093313 core:Subsidiary1 1 2023-01-01 2023-12-31 03093313 2022-12-31 03093313 core:OtherRelatedParties 2022-12-31 iso4217:GBP xbrli:pure xbrli:shares

Registration number: 03093313

Insight Biotechnology Limited
Unaudited Filleted Financial Statements
for the Year Ended 31 December 2024

Insight Biotechnology Limited

Contents

Company Information | 1
Balance Sheet | 2
Notes to the Financial Statements | 3 to 9

Insight Biotechnology Limited

Company Information

Directors | Mr Darren Croft Mrs Alison Rawlinson Mr John Rawlinson

Registered office | 110 Chandos Avenue Whetstone London N20 9DZ

Accountants | JPL Accountancy Services Ltd Chartered Accountants110 Chandos Avenue Whetstone London N20 9DZ

Insight Biotechnology Limited

(Registration number: 03093313)
Balance Sheet as at 31 December 2024

| Note | 2024 £ | 2023 £
Fixed assets |  |  |
Tangible assets | 5 | 8,692 | 10,426
Investments | 6 | 100 | 100
|  | 8,792 | 10,526
Current assets |  |  |
Stocks | 7 | 85,000 | 70,000
Debtors | 8 | 848,660 | 894,755
Cash at bank and in hand |  | 2,699,406 | 2,565,993
|  | 3,633,066 | 3,530,748
Creditors: Amounts falling due within one year | 9 | (309,976) | (295,148)
Net current assets |  | 3,323,090 | 3,235,600
Net assets |  | 3,331,882 | 3,246,126
Capital and reserves |  |  |
Called up share capital | 10 | 10,000 | 10,000
Retained earnings |  | 3,321,882 | 3,236,126
Shareholders' funds |  | 3,331,882 | 3,246,126

For the financial year ending 31 December 2024 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Directors' responsibilities:

• | The members have not required the company to obtain an audit of its accounts for the year in question in accordance with section 476; and
• | The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime. As permitted by section 444 (5A) of the Companies Act 2006, the directors have not delivered to the registrar a copy of the Profit and Loss Account.

Approved and authorised by the Board on 16 September 2025 and signed on its behalf by:

......................................... Mr John Rawlinson Director

Insight Biotechnology Limited

Notes to the Financial Statements for the Year Ended 31 December 2024

1 | General information

The company is a private company limited by share capital, incorporated in England and Wales.

The address of its registered office is:
110 Chandos Avenue
Whetstone
London
N20 9DZ

The principal place of business is:
PO Box 81693
London
N2 2GQ

These financial statements were authorised for issue by the Board on 16 September 2025.

2 | Accounting policies

Summary of significant accounting policies and key accounting estimates

The principal accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.

Statement of compliance

These financial statements have been prepared in accordance with Financial Reporting Standard 102 Section 1A smaller entities - 'The Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland' and the Companies Act 2006 (as applicable to companies subject to the small companies' regime).

Basis of preparation

These financial statements have been prepared using the historical cost convention except that as disclosed in the accounting policies certain items are shown at fair value.

Revenue recognition

Turnover comprises the fair value of the consideration received or receivable for the sale of goods and provision of services in the ordinary course of the company’s activities. Turnover is shown net of sales/value added tax, returns, rebates and discounts.
The company recognises revenue when:
The amount of revenue can be reliably measured;
it is probable that future economic benefits will flow to the entity;
and specific criteria have been met for each of the company's activities.

Foreign currency transactions and balances

Transactions in foreign currencies are initially recorded at the functional currency rate prevailing at the date of the transaction. Monetary assets and liabilities denominated in foreign currencies are retranslated into the respective functional currency of the entity at the rates prevailing on the reporting period date. Non-monetary items carried at fair value that are denominated in foreign currencies are retranslated at the rate on the date when the fair value is re-measured.
Non-monetary items measured in terms of historical cost in a foreign currency are not retranslated.

Insight Biotechnology Limited

Notes to the Financial Statements for the Year Ended 31 December 2024

Tax

The tax expense for the period comprises current tax. Tax is recognised in profit or loss, except that a change attributable to an item of income or expense recognised as other comprehensive income is also recognised directly in other comprehensive income.

The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the reporting date in the countries where the company operates and generates taxable income.

Tangible assets

Tangible assets are stated in the balance sheet at cost, less any subsequent accumulated depreciation and subsequent accumulated impairment losses.
The cost of tangible assets includes directly attributable incremental costs incurred in their acquisition and installation.

Depreciation

Depreciation is charged so as to write off the cost of assets, other than land and properties under construction over their estimated useful lives, as follows:

Asset class | Depreciation method and rate
Plant and machinery | 15% on reducing balance
Motor vehicles | 25% on reducing balance
Office equipment | 15% on reducing balance

Business combinations

Business combinations are accounted for using the purchase method. The consideration for each acquisition is measured at the aggregate of the fair values at acquisition date of assets given, liabilities incurred or assumed, and equity instruments issued by the group in exchange for control of the acquired, plus any costs directly attributable to the business combination. When a business combination agreement provides for an adjustment to the cost of the combination contingent on future events, the group includes the estimated amount of that adjustment in the cost of the combination at the acquisition date if the adjustment is probable and can be measured reliably.

Investments

Investments in equity shares which are publicly traded or where the fair value can be measured reliably are initially measured at fair value, with changes in fair value recognised in profit or loss. Investments in equity shares which are not publicly traded and where fair value cannot be measured reliably are measured at cost less impairment.
Interest income on debt securities, where applicable, is recognised in income using the effective interest method. Dividends on equity securities are recognised in income when receivable.

Cash and cash equivalents

Cash and cash equivalents comprise cash on hand and call deposits, and other short-term highly liquid investments that are readily convertible to a known amount of cash and are subject to an insignificant risk of change in value.

Insight Biotechnology Limited

Notes to the Financial Statements for the Year Ended 31 December 2024

Trade debtors

Trade debtors are amounts due from customers for merchandise sold or services performed in the ordinary course of business.
Trade debtors are recognised initially at the transaction price. They are subsequently measured at amortised cost using the effective interest method, less provision for impairment. A provision for the impairment of trade debtors is established when there is objective evidence that the company will not be able to collect all amounts due according to the original terms of the receivables.

Stocks

Stocks are stated at the lower of cost and estimated selling price less costs to complete and sell. Cost is determined using the first-in, first-out (FIFO) method.
The cost of finished goods and work in progress comprises direct materials and, where applicable, direct labour costs and those overheads that have been incurred in bringing the inventories to their present location and condition. At each reporting date, stocks are assessed for impairment. If stocks are impaired, the carrying amount is reduced to its selling price less costs to complete and sell; the impairment loss is recognised immediately in profit or loss.

Trade creditors

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Accounts payable are classified as current liabilities if the company does not have an unconditional right, at the end of the reporting period, to defer settlement of the creditor for at least twelve months after the reporting date. If there is an unconditional right to defer settlement for at least twelve months after the reporting date, they are presented as non-current liabilities.
Trade creditors are recognised initially at the transaction price and subsequently measured at amortised cost using the effective interest method.

Share capital

Ordinary shares are classified as equity. Equity instruments are measured at the fair value of the cash or other resources received or receivable, net of the direct costs of issuing the equity instruments. If payment is deferred and the time value of money is material, the initial measurement is on a present value basis.

Defined contribution pension obligation

A defined contribution plan is a pension plan under which fixed contributions are paid into a pension fund and the company has no legal or constructive obligation to pay further contributions even if the fund does not hold sufficient assets to pay all employees the benefits relating to employee service in the current and prior periods.
Contributions to defined contribution plans are recognised as employee benefit expense when they are due. If contribution payments exceed the contribution due for service, the excess is recognised as a prepayment.

3 | Staff numbers

The average number of persons employed by the company (including directors) during the year, was 16 (2023 - 15).

4 | Profit before tax

Arrived at after charging/(crediting)

Insight Biotechnology Limited

Notes to the Financial Statements for the Year Ended 31 December 2024

| 2024 £ | 2023 £
Depreciation expense | 1,733 | 1,128

5 | Tangible assets

| Office equipment £ | Motor vehicles £ | Plant and machinery £ | Total £
Cost or valuation
At 1 January 2024 | 26,239 | 4,895 | 2,985 | 34,119
At 31 December 2024 | 26,239 | 4,895 | 2,985 | 34,119
Depreciation
At 1 January 2024 | 16,157 | 4,858 | 2,678 | 23,693
Charge for the year | 1,673 | 6 | 55 | 1,734
At 31 December 2024 | 17,830 | 4,864 | 2,733 | 25,427
Carrying amount
At 31 December 2024 | 8,409 | 31 | 252 | 8,692
At 31 December 2023 | 10,082 | 37 | 307 | 10,426

6 | Investments

| 2024 £ | 2023 £
Investments in subsidiaries | 100 | 100

Subsidiaries | £
Cost or valuation
At 1 January 2024 | 1,503
Provision
At 1 January 2024 | 1,403
Carrying amount
At 31 December 2024 | 100
At 31 December 2023 | 100

Insight Biotechnology Limited

Notes to the Financial Statements for the Year Ended 31 December 2024

Details of undertakings

Details of the investments (including principal place of business of unincorporated entities) in which the company holds 20% or more of the nominal value of any class of share capital are as follows:

Undertaking | Registered office | Holding | Proportion of voting rights and shares held
|  |  | 2024 | 2023
Subsidiary undertakings
Immunodelta Ltd | 110 Chandos Avenue London N20 9DZ England | Ordinary shares | 100% | 100%

Subsidiary undertakings
Immunodelta Ltd The principal activity of Immunodelta Ltd is dormant.

7 | Stocks

| 2024 £ | 2023 £
Stocks | 85,000 | 70,000

8 | Debtors

Current | Note | 2024 £ | 2023 £
Trade debtors |  | 193,256 | 228,740
Amounts owed by related parties | 11 | 646,129 | 659,283
Prepayments |  | 9,275 | 6,732
|  | 848,660 | 894,755

Insight Biotechnology Limited

Notes to the Financial Statements for the Year Ended 31 December 2024

9 | Creditors

Creditors: amounts falling due within one year

| 2024 £ | 2023 £
Due within one year |  |
Trade creditors | 166,661 | 146,909
Taxation and social security | 106,381 | 101,761
Accruals and deferred income | 23,000 | 25,258
Other creditors | 13,934 | 21,220
| 309,976 | 295,148

10 | Share capital

Allotted, called up and fully paid shares

| 2024 | 2023
| No. | £ | No. | £
Ordinary shares of £1 each | 10,000 | 10,000 | 10,000 | 10,000

Insight Biotechnology Limited

Notes to the Financial Statements for the Year Ended 31 December 2024

11 | Related party transactions

Summary of transactions with other related parties

Insight Health Limited - a company under the control of the directors

Income and receivables from related parties

2024 | Other related parties £
Receipt of services | 650,100

2023 | Other related parties £
Receipt of services | 650,100

Loans to related parties

2024 | Other related parties £ | Total £
At start of period | 659,282 | 659,282
Repaid | (13,153) | (13,153)
At end of period | 646,129 | 646,129

2023 | Other related parties £ | Total £
At start of period | 724,832 | 724,832
Repaid | (65,550) | (65,550)
At end of period | 659,282 | 659,282